BioCentury
ARTICLE | Company News

Aegerion gains on Juxtapid update

May 17, 2013 1:32 AM UTC

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) jumped $14.73 (31%) to $61.70 on Thursday after the company said late Wednesday that the "launch metrics" for Juxtapid lomitapide are ahead of the company's internal plan and announced a price increase for the lowest doses of the homozygous familial hypercholesterolemia (hoFH) drug. At the Bank of America Merrill Lynch Healthcare Conference, Aegerion CEO Marc Beer said the company now estimates a $1 billion global market opportunity for the drug, assuming 4,000-5,000 patients on Juxtapid worldwide. Beer also said that, effective June 1, the annual price of Juxtapid will be $295,000 per patient, regardless of dose. Currently, the 5 and 10 mg doses of Juxtapid cost $235,000 and the 20, 40 and 60 mg doses cost $295,000 per patient. FDA approved Juxtapid in December. ...